Danaher to Acquire the Biopharma Business of General Electric Life Sciences for $21.4 Billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Danaher (DHR) PT Raised to $125 at Baird
February 26, 2019 9:15 AM ESTBaird analyst Richard Eastman raised the price target on Danaher (NYSE: DHR) to $125.00 (from $114.00) while maintaining an Outperform rating following the announced GE Biopharma acquisition. Eastman views the acquisition as attractive.
Adjusting for ~$1.4B in NPV tax benefits to DHR, the purchase price... More
General Electric (GE) Adds to Gains Following BioPharma Deal, Up 18%
February 25, 2019 8:09 AM ESTGeneral Electric (NYSE: GE) Adds to Gains Following BioPharma Deal, Up 18%
... MoreGeneral Electric (GE) Jumps 7% on BioPharma Sale
February 25, 2019 7:13 AM ESTGeneral Electric (NYSE: GE) gains 7% after selling is BioPharma Business to Danaher (DHR) for $21.4 billion.
... More